Pfizer withdraws application for emergency use authorisation of its COVID-19 vaccine in India

In a statement, Pfizer said it had decided to withdraw the application after a meeting with the Drug Regulatory Authority of India on 3 Feb, in which the regulator stated that there may be need for 'additional information'

Press Trust of India February 05, 2021 15:54:45 IST
Pfizer withdraws application for emergency use authorisation of its COVID-19 vaccine in India

Representational image. AP

New Delhi: Pharma major Pfizer on Friday said it has decided to withdraw its application for Emergency Use Authorisation (EUA) of its COVID-19 vaccine in India.

Pfizer was the first pharmaceutical firm to seek an emergency use authorisation from the Drugs Controller General of India (DCGI) for its COVID-19 vaccine in the country, after it secured such clearance in the UK and Bahrain.

"In pursuance of the Emergency Use Authorisation of its COVID-19 vaccine, Pfizer participated in the Subject Expert Committee meeting of the Drug Regulatory Authority of India on February 3. Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time," a company spokesperson said in a statement.

Pfizer will continue to engage with the authority and resubmit its approval request with additional information as it becomes available in the near future, the statement said.

"Pfizer remains committed to making its vaccine available for use by the Government in India and to pursuing the requisite pathway for emergency use authorisation that enables the availability of this vaccine for any future deployment," the spokesperson said.

Pfizer in its application submitted to the drug regulator in December 2020, had sought permission to import the vaccine for sale and distribution in India, besides waiver of clinical trials on Indian population in accordance with the special provisions under the New Drugs and Clinical Trials Rules, 2019, official sources had said.

Updated Date:

also read

States must form special teams to 'mercilessly' clamp down on black market of COVID-19 drugs: Centre to SC
India

States must form special teams to 'mercilessly' clamp down on black market of COVID-19 drugs: Centre to SC

In an affidavit, the Centre said the DCGI has communicated to all state drugs controllers to take strict action against hoarding and black marketing of drugs like remdesivir

WHO rejects SII’s proposal seeking extension of Covishield’s shelf life from 6 to 9 months
India

WHO rejects SII’s proposal seeking extension of Covishield’s shelf life from 6 to 9 months

The UN body has also sought a meeting with the Drugs Controller General of India to discuss the matter 10:12

Biocon gets DCGI nod for emergency use of CytoSorb to treat critical COVID-19 patients
Business

Biocon gets DCGI nod for emergency use of CytoSorb to treat critical COVID-19 patients

Biotechnology major Biocon on Wednesday said its subsidiary has received approval from the Drugs Controller General of India (DCGI) for a medical device to treat critical COVID-19 patients